{"id":"denosumab-prefilled-syringe-prolia","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypocalcemia"},{"rate":null,"effect":"Back pain"},{"rate":null,"effect":"Pain in extremity"},{"rate":null,"effect":"Musculoskeletal pain"},{"rate":null,"effect":"Cystitis"},{"rate":null,"effect":"Osteonecrosis of the jaw (rare)"}]},"_chembl":{"chemblId":"CHEMBL1237023","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting RANKL signaling, denosumab suppresses osteoclast-mediated bone resorption without directly affecting bone formation. This leads to increased bone mineral density and reduced fracture risk in patients with osteoporosis or bone loss conditions. The drug is administered as a subcutaneous injection, typically every 6 months for osteoporosis treatment.","oneSentence":"Denosumab is a monoclonal antibody that binds to RANKL (receptor activator of nuclear factor kappa-B ligand) and prevents osteoclast formation and activation, thereby reducing bone resorption.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:32:15.606Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Postmenopausal osteoporosis in women at high risk of fracture"},{"name":"Bone loss in patients with prostate cancer receiving androgen deprivation therapy"},{"name":"Bone loss in patients with breast cancer receiving aromatase inhibitors"},{"name":"Giant cell tumor of bone"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Denosumab Prefilled Syringe [Prolia]","genericName":"Denosumab Prefilled Syringe [Prolia]","companyName":"Seoul National University Bundang Hospital","companyId":"seoul-national-university-bundang-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Denosumab is a monoclonal antibody that binds to RANKL (receptor activator of nuclear factor kappa-B ligand) and prevents osteoclast formation and activation, thereby reducing bone resorption. Used for Postmenopausal osteoporosis in women at high risk of fracture, Bone loss in patients with prostate cancer receiving androgen deprivation therapy, Bone loss in patients with breast cancer receiving aromatase inhibitors.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}